It Seems Canabo Medical Inc Will Go Down. Have Another Big Decline

 It Seems Canabo Medical Inc Will Go Down. Have Another Big Decline

The stock of Canabo Medical Inc (CVE:CMM) is a huge mover today! About 68,350 shares traded hands or 97542.86% up from the average. Canabo Medical Inc (CVE:CMM) has risen 6.00% since October 23, 2016 and is uptrending. It has outperformed by 1.44% the S&P500.
The move comes after 9 months negative chart setup for the $23.71 million company. It was reported on Nov, 22 by We have $0.82 PT which if reached, will make CVE:CMM worth $711,300 less.

More notable recent Canabo Medical Inc (CVE:CMM) news were published by: which released: “Canabo Medical Inc. Announces Completion of Change of Name, Share …” on November 09, 2016, also with their article: “Four River Ventures Ltd. Announces Proposed Reverse Takeover With Canabo …” published on October 07, 2016, published: “Four River Ventures Ltd. Announces Financing Update Concerning Canabo Medical …” on September 29, 2016. More interesting news about Canabo Medical Inc (CVE:CMM) were released by: and their article: “Brazil Resources Nearly Doubles Gold Resources With Recent Acquisition” published on October 17, 2016 as well as‘s news article titled: “Cruz Capital Corp. (V.CUZ): Capitalizing on cobalt’s immense opportunity” with publication date: September 01, 2016.

Canabo Medical Inc, formerly Four River Ventures Ltd, is a Canada company, which is engaged in the provision of medical services and non-cannabinoid products for patients suffering from chronic pain and disabling illnesses through health clinics. The company has a market cap of $23.71 million. The Firm operates approximately 10 medical clinics across Canada. It has a 200.47 P/E ratio. The Company’s medical clinics are operated by qualified health care practitioners, independent medical marijuana evaluations for employers and insurers, and medical marijuana scientific research.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment